LP Pharma of Xiamen Raises $30 Million for Drugs with Mucosa/Oral Delivery

LP Pharma ( Xiamen ) raised $30 million in a B round led by state-owned SDIC Fund Management. LP focuses on developing drugs with mucosa/oral controlled delivery technology. The company, formed in 2012 by returnees, initially worked on two treatments, one for AIDS and the other an unspecified cancer indication. Joining the B round were CMB International Capital and Zhangzhou PienTzeHuang Pharma . More details.... Stock Symbol: (SHA: 600436) Share this with colleagues: // // >